Perrigo Confirms Filing of Generic Version of Astepro Nasal Spray
Perrigo announced that it has filed with the FDA an Abbreviated New Drug Application (ANDA) for Azelastine HCl nasal spray (0.15%), a generic of Astepro Nasal Spray.
Rhinitis/rhinorrhea (Intranasal Products)
SAFETY ALERT: Nostrilla Nasal Decongestant Recalled
The FDA has notified healthcare professionals and consumers that Insight Pharmaceuticals has recalled one lot of Nostrilla Nasal Decongestant (Oxymetazoline HCl nasal spray) because it may contain the bacteria Burkholderia cepacia.
NDA Accepted for BDP Nasal HFA for Allergic Rhinitis
Teva announced that the FDA has accepted its New Drug Application (NDA) for BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) after its submission in May 2011.
Phase 3 Results for Dymista for Allergic Rhinitis
Meda announced new results from its Phase 3 study of Dymista (azelastine HCl and fluticasone propionate; Meda) nasal spray for the treatment of allergic rhinitis.
NDA Accepted for Dymista for Allergic Rhinitis
The FDA has accepted for filing the NDA for Dymista (azelastine HCl and fluticasone propionate; Meda) nasal spray for the treatment of allergic rhinitis.
Phase 3 Study of Dymista for Seasonal Allergic Rhinitis
Meda announced positive results from its Phase 3 trial of Dymista (azelastine HCl and fluticasone propionate) nasal spray in patients with seasonal allergic rhinitis
Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray recalled
Procter & Gamble announced a voluntary nationwide recall of Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray (oxymetazoline HCl).
